Thierry Facon, MD, details the rationale for evaluating Isa-VRd in patients with transplant-ineligible, newly diagnosed multiple myeloma.
Thierry Facon, MD
Advertisement
Thierry Facon, MD, is a professor of hematology in the Department of Hematology at Lille University Hospital in France.
Articles by Thierry Facon, MD
Dr Facon on the Implications of Isatuximab Plus VRd in Transplant-Ineligible Newly Diagnosed Myeloma
Thierry Facon, MD, discusses clinical implications from the phase 3 IMROZ trial
Advertisement
Latest Updated Articles
Dr Facon on the Implications of Isatuximab Plus VRd in Transplant-Ineligible Newly Diagnosed MyelomaPublished: July 25th 2024 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5